Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related ...
Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...
The adrenergic antagonist improved near vision in adults with presbyopia, with over 20 hours of improvement from a single ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Phentolamine ophthalmic solution 0.75% will be evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results